<p>Bright Minds Biosciences（納斯達克股票代碼：DRUG - 獲取免費報告）的股票在 BTIG Research 發佈給客户和投資者的研究報告中重申了 “買入” 評級，Benzinga 報道。他們目前對該股票的目標價格為 147.00 美元。BTIG Research 的目標價格意味着該股票相較於之前的收盤價有 109.70% 的潛在上漲空間。</p>
<ul>
<li>生物科技行業的邊緣：2 只具有巨大潛力的股票</li>
</ul>
<p>其他幾家券商也對 DRUG 發佈了報告。Zacks Research 在 12 月 2 日的報告中將 Bright Minds Biosciences 的股票評級從 “強力買入” 下調至 “持有”。Wall Street Zen 在 3 月 21 日的研究報告中將 Bright Minds Biosciences 的股票評級從 “賣出” 上調至 “持有”。HC Wainwright 在 3 月 4 日的研究報告中將 Bright Minds Biosciences 的目標價格從 115.00 美元提升至 145.00 美元，並給予該公司 “買入” 評級。Robert W. Baird 在 2 月 13 日的報告中設定了 Bright Minds Biosciences 的目標價格為 126.00 美元。最後，Cantor Fitzgerald 在 12 月 1 日的研究報告中重申了對 Bright Minds Biosciences 的 “增持” 評級。五位投資分析師對該股票給予了買入評級，一位給予了持有評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，平均目標價格為 124.50 美元。</p>
<p><strong>查看我們關於 DRUG 的最新報告</strong></p>
<h2>Bright Minds Biosciences 股票表現</h2>
<ul>
<li>Bright Minds Biosciences 股票飆升近 1500%</li>
</ul>
<p>DRUG 在週一的開盤價為 70.10 美元。Bright Minds Biosciences 的年低為 23.17 美元，年高為 123.75 美元。該股票的市值為 6.8207 億美元，市盈率為-36.32，貝塔值為-6.03。該公司的 50 日移動平均價格為 79.18 美元，200 日移動平均價格為 71.54 美元。</p>
<p>Bright Minds Biosciences（納斯達克股票代碼：DRUG - 獲取免費報告）最後一次發佈財報是在 2 月 12 日，週四。該公司報告每股收益（EPS）為-0.70 美元，超出市場共識預期的-0.98 美元，超出幅度為 0.28 美元。作為一個整體，股票研究分析師預測 Bright Minds Biosciences 在當前財政年度的每股收益將為-1.24 美元。</p>
<h2>對 Bright Minds Biosciences 的對沖基金看法</h2>
<p>幾家機構投資者最近買入和賣出了該公司的股票。Virtu Financial LLC 在第四季度購買了 Bright Minds Biosciences 的新股份，價值約 226,000 美元。Invesco Ltd.在第四季度購買了 Bright Minds Biosciences 的新頭寸，價值約 328,000 美元。Ikarian Capital LLC 在第四季度將其在 Bright Minds Biosciences 的持股增加了 933.1%。Ikarian Capital LLC 現在擁有 159,421 股該公司的股票，價值為 12,441,000 美元，此前在上個季度又購買了 143,990 股。Wellington Management Group LLP 在第四季度獲得了 Bright Minds Biosciences 的新頭寸，價值約 1,068,000 美元。最後，Millennium Management LLC 在第四季度將其在 Bright Minds Biosciences 的股份增加了 153.6%。Millennium Management LLC 現在擁有 194,437 股該公司的股票，價值 15,174,000 美元，此前在此期間又購買了 117,756 股。40.52% 的股票由機構投資者和對沖基金持有。</p>
<h2>Bright Minds Biosciences 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Bright Minds Biosciences Inc 在納斯達克交易，股票代碼為 DRUG，是一家臨牀階段的生物技術公司，專注於開發用於心理健康和神經退行性疾病的新型小分子治療藥物。該公司的研究利用專有化學平台創建源自迷幻藥結構的調節血清素和神經保護化合物。Bright Minds 旨在通過口服治療解決重度抑鬱症、創傷後應激障礙和阿爾茨海默病等疾病的未滿足需求。</p>
<p>該公司的主要候選藥物 BMB-101 是一種口服 5-HT2A 受體調節化合物，正在臨牀開發中，針對情緒和焦慮障礙。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Bright Minds Biosciences</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Bright Minds Biosciences 嗎？</h2>
<p>在你考慮 Bright Minds Biosciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Bright Minds Biosciences 並不在名單上。</p>
<p>雖然 Bright Minds Biosciences 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

醫療業 ETF - Vanguard

標普生物技術 3 倍做多 - Direxion

DRUG

<p>BTIG Research 重申了對 Bright Minds Biosciences (NASDAQ:DRUG) 的 “買入” 評級，目標價格為 147.00 美元，暗示潛在上漲幅度為 109.70%。其他分析師的評級則各有不同，Zacks 將其評級下調至 “持有”，而 HC Wainwright 則將目標價上調至 145.00 美元。該股票開盤價為 70.10 美元，過去一年最高價為 123.75 美元。Bright Minds 專注於開發針對心理健康和神經退行性疾病的治療藥物，其主要候選藥物正在針對情緒和焦慮障礙進行臨牀開發</p>

<p>Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report)'s stock had its &#34;buy&#34; rating reiterated by equities research analysts at BTIG Research in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $147.00 target price on the stock. BTIG Research's price target would indicate a potential upside of 109.70% from the stock's previous close.</p>
<div class="lb-trans"><p>Bright Minds Biosciences（納斯達克股票代碼：DRUG - 獲取免費報告）的股票在 BTIG Research 發佈給客户和投資者的研究報告中重申了 “買入” 評級，Benzinga 報道。他們目前對該股票的目標價格為 147.00 美元。BTIG Research 的目標價格意味着該股票相較於之前的收盤價有 109.70% 的潛在上漲空間。</p>
</div><ul>
<li>Biotechs on the Brink: 2 Stocks With Huge Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技行業的邊緣：2 只具有巨大潛力的股票</li>
</ul>
</div><p>Several other brokerages have also issued reports on DRUG. Zacks Research lowered shares of Bright Minds Biosciences from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, December 2nd. Wall Street Zen raised shares of Bright Minds Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, March 21st. HC Wainwright boosted their price target on shares of Bright Minds Biosciences from $115.00 to $145.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, March 4th. Robert W. Baird set a $126.00 price objective on shares of Bright Minds Biosciences in a report on Friday, February 13th. Finally, Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating on shares of Bright Minds Biosciences in a research report on Monday, December 1st. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $124.50.</p>
<div class="lb-trans"><p>其他幾家券商也對 DRUG 發佈了報告。Zacks Research 在 12 月 2 日的報告中將 Bright Minds Biosciences 的股票評級從 “強力買入” 下調至 “持有”。Wall Street Zen 在 3 月 21 日的研究報告中將 Bright Minds Biosciences 的股票評級從 “賣出” 上調至 “持有”。HC Wainwright 在 3 月 4 日的研究報告中將 Bright Minds Biosciences 的目標價格從 115.00 美元提升至 145.00 美元，並給予該公司 “買入” 評級。Robert W. Baird 在 2 月 13 日的報告中設定了 Bright Minds Biosciences 的目標價格為 126.00 美元。最後，Cantor Fitzgerald 在 12 月 1 日的研究報告中重申了對 Bright Minds Biosciences 的 “增持” 評級。五位投資分析師對該股票給予了買入評級，一位給予了持有評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，平均目標價格為 124.50 美元。</p>
</div><p><strong>View Our Latest Report on DRUG</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 DRUG 的最新報告</strong></p>
</div><h2>Bright Minds Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 股票表現</h2>
</div><ul>
<li>Bright Minds Biosciences Stock Surges Almost 1,500%</li>
</ul>
<div class="lb-trans"><ul>
<li>Bright Minds Biosciences 股票飆升近 1500%</li>
</ul>
</div><p>DRUG opened at $70.10 on Monday. Bright Minds Biosciences has a one year low of $23.17 and a one year high of $123.75. The stock has a market capitalization of $682.07 million, a PE ratio of -36.32 and a beta of -6.03. The business's 50 day moving average price is $79.18 and its 200 day moving average price is $71.54.</p>
<div class="lb-trans"><p>DRUG 在週一的開盤價為 70.10 美元。Bright Minds Biosciences 的年低為 23.17 美元，年高為 123.75 美元。該股票的市值為 6.8207 億美元，市盈率為-36.32，貝塔值為-6.03。該公司的 50 日移動平均價格為 79.18 美元，200 日移動平均價格為 71.54 美元。</p>
</div><p>Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last posted its earnings results on Thursday, February 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.28. As a group, equities research analysts forecast that Bright Minds Biosciences will post -1.24 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Bright Minds Biosciences（納斯達克股票代碼：DRUG - 獲取免費報告）最後一次發佈財報是在 2 月 12 日，週四。該公司報告每股收益（EPS）為-0.70 美元，超出市場共識預期的-0.98 美元，超出幅度為 0.28 美元。作為一個整體，股票研究分析師預測 Bright Minds Biosciences 在當前財政年度的每股收益將為-1.24 美元。</p>
</div><h2>Hedge Funds Weigh In On Bright Minds Biosciences</h2>
<div class="lb-trans"><h2>對 Bright Minds Biosciences 的對沖基金看法</h2>
</div><p>Several institutional investors have recently bought and sold shares of the company. Virtu Financial LLC purchased a new stake in Bright Minds Biosciences during the fourth quarter worth about $226,000. Invesco Ltd. purchased a new position in shares of Bright Minds Biosciences in the fourth quarter valued at approximately $328,000. Ikarian Capital LLC grew its holdings in shares of Bright Minds Biosciences by 933.1% in the fourth quarter. Ikarian Capital LLC now owns 159,421 shares of the company's stock valued at $12,441,000 after purchasing an additional 143,990 shares in the last quarter. Wellington Management Group LLP acquired a new position in shares of Bright Minds Biosciences in the fourth quarter valued at approximately $1,068,000. Finally, Millennium Management LLC increased its stake in Bright Minds Biosciences by 153.6% during the 4th quarter. Millennium Management LLC now owns 194,437 shares of the company's stock worth $15,174,000 after buying an additional 117,756 shares during the period. 40.52% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家機構投資者最近買入和賣出了該公司的股票。Virtu Financial LLC 在第四季度購買了 Bright Minds Biosciences 的新股份，價值約 226,000 美元。Invesco Ltd.在第四季度購買了 Bright Minds Biosciences 的新頭寸，價值約 328,000 美元。Ikarian Capital LLC 在第四季度將其在 Bright Minds Biosciences 的持股增加了 933.1%。Ikarian Capital LLC 現在擁有 159,421 股該公司的股票，價值為 12,441,000 美元，此前在上個季度又購買了 143,990 股。Wellington Management Group LLP 在第四季度獲得了 Bright Minds Biosciences 的新頭寸，價值約 1,068,000 美元。最後，Millennium Management LLC 在第四季度將其在 Bright Minds Biosciences 的股份增加了 153.6%。Millennium Management LLC 現在擁有 194,437 股該公司的股票，價值 15,174,000 美元，此前在此期間又購買了 117,756 股。40.52% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Bright Minds Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.</p>
<div class="lb-trans"><p>Bright Minds Biosciences Inc 在納斯達克交易，股票代碼為 DRUG，是一家臨牀階段的生物技術公司，專注於開發用於心理健康和神經退行性疾病的新型小分子治療藥物。該公司的研究利用專有化學平台創建源自迷幻藥結構的調節血清素和神經保護化合物。Bright Minds 旨在通過口服治療解決重度抑鬱症、創傷後應激障礙和阿爾茨海默病等疾病的未滿足需求。</p>
</div><p>The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.</p>
<div class="lb-trans"><p>該公司的主要候選藥物 BMB-101 是一種口服 5-HT2A 受體調節化合物，正在臨牀開發中，針對情緒和焦慮障礙。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Bright Minds Biosciences</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Bright Minds Biosciences</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=DRUG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bright Minds Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Bright Minds Biosciences 嗎？</h2>
</div><p>Before you consider Bright Minds Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Bright Minds Biosciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bright Minds Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Bright Minds Biosciences 並不在名單上。</p>
</div><p>While Bright Minds Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Bright Minds Biosciences 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Bright Minds Biosciences（NASDAQ:DRUG）被 BTIG Research 給予買入評級